trial · primary record
EO2463
Follicular Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 80 |
| Primary completion | 2034-05-30 |
| Primary endpoint | Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment | |
| Registry ID | NCT04669171 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:49.055Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04669171
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.